Strategy | Financing | Macro & Markets
Private Placement / Financing Transactions

Abridge: The company raised $354 million of Series E venture funding in a deal led by Andreessen Horowitz on June 24, 2025. Khosla Ventures and Other undisclosed investors also participated in the round. The company is a developer of a healthcare application designed to bring context and understanding to every medical conversation.

Neuron23: The company raised $96.5 million of Series D venture funding from Redmile Group, SoftBank Investment Advisers and Kleiner Perkins on June 24, 2025. HBM Healthcare Investments, Westlake Village BioPartners, Acorn Bioventures and Blue Owl Capital also participated in the round. The company is a developer of an artificial intelligence-based drug discovery model designed for genetically defined neurological and immunological diseases.

Arthrosi Therapeutics: The company raised $60.8 million of venture funding from undisclosed investors on June 23, 2025. The company is a developer of biotechnology drugs designed to reduce flare and tophi in gout patients.

Certify: The company raised $40 million of Series B venture funding in a deal led by Transformation Capital on June 26, 2025. Upfront Ventures, General Catalyst and SemperVirens Venture Capital also participated in the round. The company is a developer of a data intelligence platform designed to automate provider licensing and credentialing.

Mandolin: The company raised $40 million of Series A venture funding in a deal led by Greylock on June 25, 2025. Maverick Ventures, SignalFire, SV Angel, Timeless Ventures, Jerry Yang and Guillermo Rauch also participated in the round. The company is a developer of automated back-office tools intended for managing specialty drug administration processes.

Phamily: The company raised $25 million of venture funding from Level Equity, Hustle Fund and Darwin Venture Management on June 24, 2025. The company is a developer of an artificial intelligence-enabled care management and patient communication platform designed to manage patient data.

EnsoData: The company raised $20 million of Series B venture funding in a deal led by Questa Capital on June 25, 2025. Inspire Medical Systems, Zetta Venture Partners, and Supermoon Capital also participated in the round. The company is an operator of a healthcare technology business intended to provide artificial intelligence-powered software services to improve the quality of care and patient outcomes.

BiomEdit: The company raised $16 million of Series B venture funding from undisclosed investors on June 26, 2025. The company is a developer of a microbiome innovation platform designed to discover and develop animal health products.

BluebriX: The company raised $15 million of venture funding from undisclosed investors on June 25, 2025. The company is a healthcare technology business that specializes in value-based care solutions.

SuperBill: The company raised $15 million of Series A venture funding through a combination of convertible debt and equity on June 24, 2025. The $12 million of Series A equity portion was led by SignalFire with participation from BoxGroup, Slow Ventures and Scrub Capital. The company is a developer of healthcare communication automation tools designed for streamlining interactions between providers and payers.

Dash Technologies: The company raised $11 million of venture funding from undisclosed investors on June 26, 2025. The company is a developer of a clinical bioanalysis platform that offers AI, robotics, and integrated software to streamline processes, reduce costs, and accelerate time to market in the pharmaceutical and healthcare industries.

Axiles Bionics: The company raised EUR 6 million of Series A venture funding in a deal led by PE Group on June 24, 2025. European Innovation Council, Finance&Invest.Brussels, and other undisclosed investors also participated in the round. The company is a developer of robotic prosthesis technology designed to improve the quality of life for amputees.

RedShiftBio: The company raised $5.9 million of venture funding from undisclosed investors on June 25, 2025. The company is a developer of bio-analytical instrumentation designed to transform protein characterization.

EpiHerd: The company raised EUR 3.6 million of venture funding in a deal led by The First Thirty Ventures on June 26, 2025. Generation-RE Holdings and Endgame Capital also participated in the round. The company is a developer of an epigenomics technology designed to enhance productivity, efficiency, and sustainability in the livestock industry.

Limber: The company raised $3.7 million of venture funding from undisclosed investors on June 23, 2025. The company is a developer of prosthetic and orthotic devices designed to support the healthcare industry.

Oria Bioscience: The company raised EUR 2.7 million of venture funding from Cenitz and other investors on June 25, 2025. The company is a developer of organelle-based research tools designed for pharmaceutical and drug discovery applications.

MTF Biologics: The company raised an undisclosed amount of venture funding from Ben Franklin Technology Partners of Northeastern Pennsylvania on June 24, 2025. The company is an operator of a biotechnology firm focused on tissue and organ transplantation and related research.

Sanmai Technologies: The company raised an undisclosed amount of venture funding in a deal led by Reid Hoffman on June 24, 2025. The company is a developer of a neurotechnology platform designed for non-invasive ultrasound neurotherapeutics for mental health and neurological disorders.


M&A Transactions

SomaLogic / Illumina: The company, a subsidiary of Standard BioTools, reached a definitive agreement to be acquired by Illumina for $425 million on June 23, 2025. The company is a developer of proteomic technology designed to commercialize life science research tools and clinical diagnostic products.

Enzo Biochem / Battery Ventures: The company entered into a definitive agreement to be acquired by Battery Ventures through a $37 million public-to-private LBO on June 24, 2025. Enzo Biochem Inc is a bioscience company that manufactures, develops and sells proprietary solutions and platforms to clinical laboratories.

Impact Biomedical / Dr.Ashleys: The company reached a definitive agreement to be acquired by Dr.Ashleys through a reverse merger on June 24, 2025. Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases.

PredictionHealth / Prompt: The company was acquired by Prompt for an undisclosed amount on June 23, 2025. The company is a developer of artificial intelligence-assisted software designed to simplify the production of physician documentation and improve patient care.

Synthego / Perceptive Advisors: The company entered into a definitive agreement to be acquired by Perceptive Advisors through an LBO on June 26, 2025 for an undisclosed amount. The company is a developer of a precision genome engineering platform designed to accelerate and optimize drug discovery research.

Turnstone Biologics / Xoma: The company reached a definitive agreement to be acquired by Xoma for an undisclosed amount on June 27, 2025. Turnstone Biologics is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors.

Validate Health / Oliver Wyman: The company reached a definitive agreement to be acquired by Oliver Wyman, a subsidiary of Marsh & McLennan Companies, for an undisclosed amount on June 25, 2025. The company is a developer of actuarial risk modeling software intended for managed care organizations.


Source: Pitchbook Data, Inc.

Categories

Archives